The strong efficacy data in frontline AML supports ziftomenib's potential label expansion, which could significantly increase peak sales. Monitor EHA 2026 presentation on June 14 for updated durability and safety data, and the virtual investor call on June 3 for additional context. The Phase 3 KOMET-017 enrollment progress will be a key catalyst.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $9.68entry
- T+1 · 6mo ago −2.07%α −2.64% · $9.48
- T+5 · 6mo ago −4.96%α −5.04% · $9.20
- T+20 · 5mo ago −10.33%α −8.60% · $8.68
- T+60 · 3mo ago −4.13%α −8.52% · $9.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 2026. The 99-patient dataset shows high CRc rates (90-96%) and deep MRD negativity (>80%) across NPM1-m and KMT2A-r subtypes, with median duration of CRc not reached in NPM1-m patients at ~15 months follow-up. The Phase 3 KOMET-017 trial is enrolling, with potential for accelerated FDA review in 2028.
Key Facts
- Oral presentation at EHA 2026 on June 14 will feature 99-patient dataset with extended follow-up
- CRc rates: 96% (NPM1-m) and 90% (KMT2A-r) in frontline AML
- MRD-negativity rates: 83% (NPM1-m) and 82% (KMT2A-r) among CRc responders
- Median duration of CRc not reached in NPM1-m at 14.9 months median follow-up
- Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028
- Ziftomenib already FDA-approved as KOMZIFTI for R/R NPM1-m AML
Financial Impact
No financial figures disclosed; potential to expand ziftomenib's addressable market from R/R to frontline AML, which represents a larger patient population
Risk Factors
- Differentiation syndrome remains a boxed warning risk (26% incidence in R/R AML)
- Phase 3 KOMET-017 trial may fail to replicate Phase 1 results
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Potential for accelerated FDA review in 2028 is aspirational and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293020 |
Track record
29 reports on KURA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers